ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 30, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMN), a biotechnology...
Neuroscience
AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination
Financing represents minimum cash required to consummate the business combination and bridge AEON through key episodic migraine data readoutIRVINE, Calif.,...
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to...
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to...
Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004
-- Represents the final step before submission of Investigational New Drug (IND) application to FDA, expected in the second half...
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 29, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMNRFXF) (“ProMIS” or...
BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation
Trial met primary endpoint with the 60 mcg dose, with BXCL501 demonstrating a statistically significant 39% greater reduction in PEC...
Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
Advisory committee voted 10 for and 4 against that evidence from the Phase III MOVE study show palovarotene is an...
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development...
Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium
Former Awardee and Artelo Employee, Professor Saoirse O’Sullivan will Present the 2023 Recipient with the AwardSOLANA BEACH, Calif., June 28,...
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer...
Aurora Spine Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study
Carlsbad, Calif, June 28, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a...
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
Results Show Positive Treatment Effect of CT1812 on Global and Regional Brain Activity Management Holding Webcast Conference Call at 8:00am...
Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...
Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023
R&D Retina Day featuring several retina experts will take place from 10:00 AM – 12:00 PM EDT at the Lotte...
Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
First late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase...
BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Long-time Collaborators Botond Roska and José-Alain Sahel Win International Prize for Translational Neuroscience
J-A. Sahel (left)_B.Roska (right) J-A. Sahel (left)_B.Roska (right)Basel, Switzerland, June 22, 2023 --In recognition of their pioneering work on restoring...
BrainsWay Announces Significant Expansion in Western and Central U.S.
30 Deep TMS™ Devices Ordered by Large Mental Health-Focused TMS NetworkBURLINGTON, Mass. and JERUSALEM, June 21, 2023 (GLOBE NEWSWIRE) --...
Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions
LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain INPEFA recently approved for treatment of heart failure THE...